New GLP-1 Receptor Agonists (Diabetes & Weight) treatments in trials

Semaglutide, Tirzepatide, Liraglutide — diabetes & weight management therapies. Track the treatments still in clinical testing and see which are closest to an FDA decision.

114Closest to approval (Phase 3)

163Mid-stage (Phase 2)

112Early stage (Phase 1)

1,953Total recruiting

In one line

1,953 glp-1 receptor agonists (diabetes & weight) trials are recruiting right now, 114 of them in Phase 3 — the stage immediately before an FDA decision.

Recruiting now

Twelve of the currently recruiting studies. Open one for a plain-English summary of who it is for and what it involves.

NCT06704672NARecruitingClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes MellitusSponsorHoffmann-La RocheEnrolling270Summary NCT06291766NARecruitingGestational Diabetes After Gastric Bypass SurgerySponsorRegion SkaneEnrolling120Summary NCT05089890NARecruitingClinical Investigation of Sorbact® DressingsSponsorABIGO Medical ABEnrolling30Summary NCT07375069RecruitingCharacterization of Cardiovascular Risk Profile and Therapeutic Management in Patients With Type 2 Diabetes Mellitus in ItalySponsorFederico II UniversityEnrolling3,000Summary NCT03161652Phase 2RecruitingEffect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular EdemaSponsorCarmen ClappEnrolling120Summary NCT07351058Phase 3RecruitingA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesSponsorHoffmann-La RocheEnrolling1,600Summary NCT06879834RecruitingAssessing of Artificial Intelligence-based Software Platform for Diabetic Retinopathy ScreeningSponsorThe Filatov Institute of Eye Diseases and Tissue TherapyEnrolling200Summary NCT06046833NARecruitingContinuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 DiabetesSponsorSamita GargEnrolling50Summary NCT05546138RecruitingCharacterization and Prediction of Early Onset Diabetic Peripheral NeuropathySponsorAalborg University HospitalEnrolling200Summary NCT04932928NARecruitingPatient-Driven Lifestyle Modification Using FreeStyle Libre in Type 2 Diabetes PatientsSponsorSeoul National University HospitalEnrolling126Summary NCT06319716NARecruitingLINK-IT: Leveraging vIdeos and commuNity Health worKers to Improve Diabetes OuTcomesSponsorNYU Langone HealthEnrolling540Summary NCT06748963NARecruitingFasted Exercise Training in Type 1 Diabetes (FED-T1D)SponsorUniversity of AlbertaEnrolling20Summary

View all 1,953 on ClinicalTrials.gov

Already approved for this area

GLP-1 Receptor Agonists

Ozempic, Mounjaro, Wegovy, Zepbound — approved products with their NDC records and billing codes.

Open the class

Every NDC in this class

The FDA registry filtered to glp-1 receptor agonists, with packaging and 11-digit billing conversions.

Search the directory

Loading the trial explorer…